A Combination Treatment for Patients with Advanced Renal Cell Carcinoma

In this session, Jennifer Hasiak, PharmD (Hematology & Oncology Consultants), examines cabozantinib (CABOMETYX®) plus nivolumab (OPDIVO®) in first-line advanced renal cell carcinoma, bringing the clinical evidence into conversation with the day-to-day realities of monitoring, adverse-reaction management and patient education.

You’ll learn about:

• How the efficacy and safety data inform the use of cabozantinib plus nivolumab in first-line aRCC
• Key considerations when monitoring for select adverse reactions
• Approaches to managing certain adverse reactions associated with cabozantinib monotherapy, cabozantinib plus nivolumab, and nivolumab and hyaluronidase-nvhy (OPDIVO QVANTIG™)
• How patient education can support earlier communication and informed treatment management
• Resources available to support providers, patients and caregivers

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.